Dicerna Pharmaceuticals, Inc.
Methods and compositions for the specific inhibition of .beta.-catenin by double-stranded RNA

Last updated:

Abstract:

This invention relates to compounds, compositions, and methods useful for reducing .beta.-catenin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.

Status:
Grant
Type:

Utility

Filling date:

9 Jul 2018

Issue date:

7 Apr 2020